PureTech Health plc

Director's Dealing • Jul 4, 2025

National Storage Mechanism | Additional information

RNS Number : 7007P

PureTech Health PLC

04 July 2025

04 July 2025

PureTech Health plc

PDMR Notifications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases , announces that awards of restricted share units ("RSUs") granted by PureTech on 26 June 2024 and 08 November 2024 to certain non-executive directors ("PDMRs") pursuant to its Performance Share Plan ("PSP") vested in full on 13 June 2025 the day immediately preceding the Company's Annual General Meeting of Stockholders . Each PDMR received vested ordinary shares on 01 July 2025 .

The Company's total issued ordinary share capital is 257,927,489 shares after the share issuance to the PDMRs, 17,234,267 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Raju Kucherlapati

John LaMattina

Robert Langer

Kiran Mazumdar-Shaw

Sharon Barber-Lui

Michele Holcomb

2

Reason for the notification

a)

Position/status

Non-Executive Directors

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74

b)

Nature of the transaction

Issuance of ordinary shares in settlement of certain vested RSUs under the PureTech Health Performance Share Plan.

c)

Price(s) and volume(s)

Recipient	Price	Amount
Raju Kucherlapati	0.01 GBP	59,202 ordinary shares
John LaMattina	0.01 GBP	59,202 ordinary shares
Robert Langer	0.01 GBP	59,202 ordinary shares
Kiran Mazumdar-Shaw	0.01 GBP	59,202 ordinary shares
Sharon Barber-Lui	0.01 GBP	59,202 ordinary shares
Michele Holcomb	0.01 GBP	50,000 ordinary shares

d)

Aggregated information

-	Aggregated volume

-	Price

Price	Aggregate Volume
0.01 GBP	346,010 ordinary shares

e)

Date of the transaction

01 July 2025

f)

Place of the transaction

London Stock Exchange (XLON)

About PureTech Health 

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. 

For more information, visit  www.puretechhealth.com  or connect with us on X (formerly Twitter) @puretechh.

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPUUWMUPAGRW